Furthermore, BRAFi are limited to patients with BRAF-mutant CM and MEKi show modest effects in BRAF wild-type tumors (Ascierto et al., 2013; Dummer et al., 2017; Lebbé et al., 2020; Urbonas et al., 2019) and rare melanoma subtypes (Chacón et al., 2020). The gene discussed is BRAF; the disease is melanoma.